Abstract
We sought to examine the microstructural white matter differences in patients with focal to bilateral tonic-clonic seizures (FBTCS), compared to those with focal epilepsy without FBTCS, and control participants. Using a superior tract segmentation model, we obtained track-weighted tensor-metrics (TW-TM), implemented through an automated pipeline for image analysis and tract reconstruction. Analysis of covariance was used to compare group differences in the TW-TM for whole-tract and hemispheric tract measurements. We identified several white matter regions that displayed significantly altered white matter in patients with focal epilepsy compared to controls. Further, patients without FBTCS had significantly increased white matter disruption in the inferior fronto-occipital fascicle and the striato-occipital tract. In contrast, patients with FBTCS were more similar to healthy controls in most regions, except for distinct alterations in the inferior cerebellar region compared to the non-FBTCS group and controls. Our study revealed marked alterations in a range of subcortical tracts widely considered critical in the genesis of seizures in focal epilepsy. Our application of TW-TM in a new clinical dataset enabled the identification of specific tracts that may act as a predictive biomarker to distinguish patients who are likely to develop FBTCS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CM acknowledges scholarship support from the Nerve Research Foundation, University of Sydney. AD acknowledges funding from St Vincent's Hospital. OK acknowledges the partial support provided by The University of Sydney through a SOAR Fellowship and Microsoft's partial support through a Microsoft AI for Accessibility grant. CW acknowledges research funding from the Nerve Research Foundation, University of Sydney. All authors would like to acknowledge the research funding support from UCB Australia Pty Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Sydney Local Health District (SLHD) Royal Prince Alfred Hospital (RPAH) gave ethical approval (ID: X14-0347; & HREC/14/RPAH/467).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version has been updated to move the Results section to follow the Introduction, followed by the Discussion and then Methods. Table 1 has been moved to page 3. Additional figures (Fig 1 and 2) have been added to the Results section. The figure that was formerly Figure 1 has now been changed to Figure 3.
Data Availability
The data that support the findings of this study are available from Royal Prince Alfred Hospital/The University of Sydney. However, restrictions apply to the availability of these data, which were used under license/ethical approval for the current study, and so are not publicly available.
